ArticleActa oncologica (Stockholm, Sweden)2025
Pulmonary nodules in Denmark: occurrence, resource use, and risk of lung cancer and death.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Feasibility of lung cancer screening in low-risk populations of the Nordic countries.Acta oncologica (Stockholm, Sweden) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeLittle is known about how pulmonary nodules are managed in routine clinical care. We examined their occurrence, the use of computed tomography (CT) scans, referrals to cancer pathways, and the risk of lung cancer and death post-diagnosis. PATIENTS/MATERIAL AND
methodsWe conducted a population-based cohort study using Danish health registry data. We identified all adults with a first-time pulmonary nodule diagnosis from 2018 to 2022. We examined the incidence of pulmonary nodules using age- and sex-standardized incidence rates (SIRs). We used the Aalen-Johansen estimator to calculate the probability of receiving a chest CT scan, a cancer patient pathway referral, the risk of lung cancer, and mortality within 12 months after a nodule diagnosis.
resultsWe identified 43,209 patients with a pulmonary nodule diagnosis. The age- and sex-SIR of pulmonary nodules was 197 per 100,000 person-years in 2018, declining to 186 per 100,000 person-years in 2022. Within 12 months after a nodule diagnosis, 68.3% of the cohort underwent at least one chest CT scan, with 51.0% receiving a low-dose chest CT scan and 7.2% receiving a referral to a lung cancer patient pathway. The 12-month lung cancer risk was 3.6% (95% CI, 3.4 to 3.8%), with the highest risk for stage I lung cancer, and the mortality was 7.0% (95% CI, 6.8 to 7.3%).
interpretationThe incidence of pulmonary nodules remained relatively stable from 2018 to 2022. More than 30% of patients with nodules lacked a chest CT scan within 12 months after a pulmonary nodule diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.